OncoCyte Corp logo

OncoCyte Corp

€ 0.35 (+4.79%) Feb 7
P/E:
At Loss
P/B:
0.62
Market Cap:
€ 44.23M ($ 47.48M)
Enterprise V:
€ 17.48M ($ 18.76M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap €:
44.23M
Market Cap $:
47.48M
PE Ratio:
At Loss
Avg Vol (2-Month):
-
Enterprise Value €:
17.48M
Enterprise Value $:
18.76M
PB Ratio:
0.62

Business Description

Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Name Current Vs Industry Vs History
Cash-To-Debt 8.63
Equity-to-Asset 0.49
Debt-to-Equity 0.05
Debt-to-EBITDA -0.06
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.67
Distress
Grey
Safe
Beneish M-Score -0.69
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 46.85
9-Day RSI 45.8
14-Day RSI 46.88
6-1 Month Momentum % -33.51
12-1 Month Momentum % -56.6

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.83
Quick Ratio 2.83
Cash Ratio 2.51
Days Inventory 12.68
Days Sales Outstanding 75.58
Days Payable 87.78

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -31.4
Name Current Vs Industry Vs History
Gross Margin % -8.05
Operating Margin % -707.4
Net Margin % -788.06
ROE % -82.55
ROA % -39.75
ROIC % -44.65
ROC (Joel Greenblatt) % -636.25
ROCE % -43.33

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 4.97
PB Ratio 0.62
EV-to-EBIT -0.29
EV-to-EBITDA -0.32
EV-to-Revenue 2.33
EV-to-Forward-Revenue 10.19
EV-to-FCF -0.4
Earnings Yield (Greenblatt) % -342.86

Financials (Next Earnings Date:2023-03-10 Est.)

FRA:7OC's 30-Y Financials

How OncoCyte Corp (FRA:7OC) Makes Its Money

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Executives

Details

Valuation chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 7.452
EPS (TTM) (€) -0.592
Beta 0.36
Volatility % 50.54
14-Day RSI 46.88
14-Day ATR (€) 0.026403
20-Day SMA (€) 0.3764
12-1 Month Momentum % -56.6
52-Week Range (€) 0.22 - 1.6
Shares Outstanding (Mil) 118.64

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

OncoCyte Corp Filings

Document Form Filing Date
No Filing Data

OncoCyte Corp Stock Events

Event Date Price(€) Daily Change %
No Event Data

Press Release

Subject Date
No Press Release